General Information of the Drug (ID: M6APDG03601)
Name
Hebervis
Synonyms
CIGB-400; EGF (buccal local, mucositis), CIGB; EGF (rectal, proctitis), CIGB
    Click to Show/Hide
Status
Investigative
TTD Drug ID
D09SBY
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Epidermal growth factor (EGF)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Epidermal growth factor (EGF) is a therapeutic target for Hebervis. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hebervis through regulating the expression of Epidermal growth factor (EGF). [1], [2]
References
Ref 1 METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF/RAD51 axis. Elife. 2022 May 3;11:e75231. doi: 10.7554/eLife.75231.
Ref 2 Repurposing of the epidermal growth factor. Journal of Commercial Biotechnology (2011) 17, 45-52.